1027 related articles for article (PubMed ID: 10482196)
1. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
4. Antibodies as molecular target-based therapy: trastuzumab.
Tokuda Y
Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
[TBL] [Abstract][Full Text] [Related]
5. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials of single-agent trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):20-6. PubMed ID: 11049053
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin).
Osoba D; Burchmore M
Semin Oncol; 1999 Aug; 26(4 Suppl 12):84-8. PubMed ID: 10482198
[TBL] [Abstract][Full Text] [Related]
8. Current and planned clinical trials with trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
[TBL] [Abstract][Full Text] [Related]
9. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; PalangiƩ T; Pouillart P
Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
12. [Breast cancer].
Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
[TBL] [Abstract][Full Text] [Related]
13. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
15. [Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2].
Tajima T; Suzuki Y; Tokuda Y
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1132-7. PubMed ID: 12145992
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
17. [Herceptin-based therapy for breast cancer].
Tokuda Y; Saito Y; Suzuki Y
Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
19. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]